Bispham Barbara Harlin sold $22K of CBIO
Bispham Barbara Harlin (See Remarks) sold 1,218 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.99 on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the record of insider activity: 1,218 shares sold at $17.9900/share, total ~$21.9K, under a pre-arranged 10b5-1 plan.
Market read
Primarily a sentiment/positioning datapoint; not a fundamental catalyst like earnings, guidance, or regulatory action.
What to watch
The article provides no context on total insider holdings beyond post-transaction shares, no reason for sale, and no linkage to any corporate event—so the signal may be overstated.
Background
This is an SEC Form 4 insider transaction for Crescent Biopharma (CBIO) by an officer, reported via EDGAR.
Ticker impact
Crescent Biopharma insider Bispham Barbara Harlin filed a Form 4 open-market sale of 1,218 shares at $17.99 on 2026-06-22.
Low likelihood of a sustained price move solely from this Form 4.
The filing is an open-market sale and explicitly states a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider sales can coincide with periods of reduced confidence or liquidity needs; traders may still monitor for follow-on selling.
Key entities
- issuerCrescent Biopharma, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderBispham Barbara Harlin
Officer who sold 1,218 shares in an open-market transaction under a 10b5-1 plan.
